Entities / Company
Cognition Therapeutics (United States).
company in Pittsburgh, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 31
What's happening
Gone quiet
No new reports in 90+ days-
High cash burn rate reduces cash runway for Cognition Therapeutics.Speculative1 report
-
Cognition Therapeutics published the results of the Phase 2 SEQUEL study on July 21, 2025, showing that the drug zervimesine protects neurons and synapses in the context of Alzheimer's disease.Some support4 reports
-
Cognition Therapeutics received grant support from the NIH segment on July 12, 2025, for a clinical study.Some support2 reports
-
Cognition Therapeutics received minutes from the U.S. FDA, confirming that their proposed Phase 3 trial design supports the eventual NDA filing.Some support2 reports
-
Cognition Therapeutics regained compliance with Nasdaq minimum bid price rules on August 27, 2025.Some support1 report
-
Cognition Therapeutics is conducting the Phase 2 START Study.Some support1 report
-
Cognition Therapeutics announced that Titan Partners Group was appointed as their sole placement agent on September 3, 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Cognition Therapeutics (United States) this week
News at the entities that move Cognition Therapeutics (United States) most-
FDA StructuralWaters Corporation and LabCorp are partnering to expand access to FDA-approved HPV testing options.Moves Cognition Therapeutics (United States)
-
Austria Shared contextKathleen Jennings filed a civil lawsuit on behalf of Delaware against an Austria-based manufacturer.Moves Cognition Therapeutics (United States)
-
Dementia Mentioned togetherCognitive decline is preventing individuals from managing their finances.Moves Cognition Therapeutics (United States)
Connections
The 3 strongest of 31, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Cognition Therapeutics relies on the FDA for regulatory review and approval of its drug development.
-
Austria Shared context
Cognition Therapeutics presented study results at a conference held in Vienna, Austria.
-
Dementia Mentioned together
Cognition Therapeutics is noted for developing drugs to treat neurodegenerative disorders like Dementia.
History
Events by the month they beganJune 2026
7 events- High cash burn rate reduces cash runway for Cognition Therapeutics.
- Cognition Therapeutics published the results of the Phase 2 SEQUEL study on July 21, 2025, showing that the drug zervimesine protects neurons and synapses in the context of Alzheimer's disease.
- Cognition Therapeutics received grant support from the NIH segment on July 12, 2025, for a clinical study.
- Cognition Therapeutics received minutes from the U.S. FDA, confirming that their proposed Phase 3 trial design supports the eventual NDA filing.
- Cognition Therapeutics regained compliance with Nasdaq minimum bid price rules on August 27, 2025.
- Cognition Therapeutics is conducting the Phase 2 START Study.
- Cognition Therapeutics announced that Titan Partners Group was appointed as their sole placement agent on September 3, 2025.